XML 37 R20.htm IDEA: XBRL DOCUMENT
v3.22.4

Note 12 - Segment Information | 9 Months Ended
--- | ---
Dec. 31, 2022
Notes to Financial Statements |
Segment Reporting Disclosure [Text Block] | Note 12. S egment Information The following tables set forth our segment information:
|  | Three Months Ended December 31, |  |  | Nine Months Ended December 31, |
|  | 2022 |  |  | 2021 |  |  | 2022 |  |  | 2021 |
Revenues: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Clinical Genomics |  | $ | 15,585 |  |  | $ | 16,485 |  |  | $ | 48,525 |  |  | $ | 16,485 |
Sterilization and Disinfection Control |  |  | 16,283 |  |  |  | 13,831 |  |  |  | 48,021 |  |  |  | 43,014 |
Biopharmaceutical Development |  |  | 11,646 |  |  |  | 12,756 |  |  |  | 34,757 |  |  |  | 32,188 |
Calibration Solutions |  |  | 10,773 |  |  |  | 11,624 |  |  |  | 32,186 |  |  |  | 33,769 |
Total revenues (a) |  | $ | 54,287 |  |  | $ | 54,696 |  |  | $ | 163,489 |  |  | $ | 125,456 |
Gross profit |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Clinical Genomics |  | $ | 8,045 |  |  | $ | 3,924 |  |  | $ | 26,535 |  |  | $ | 3,924 |
Sterilization and Disinfection Control |  |  | 11,614 |  |  |  | 9,945 |  |  |  | 34,581 |  |  |  | 31,859 |
Biopharmaceutical Development |  |  | 7,359 |  |  |  | 8,768 |  |  |  | 21,993 |  |  |  | 20,061 |
Calibration Solutions |  |  | 5,740 |  |  |  | 6,090 |  |  |  | 17,411 |  |  |  | 18,330 |
Reportable segment gross profit |  |  | 32,758 |  |  |  | 28,727 |  |  |  | 100,520 |  |  |  | 74,174 |
Corporate and Other (b) |  |  | 7 |  |  |  | (100 | ) |  |  | (28 | ) |  |  | (196 | )
Gross profit |  | $ | 32,765 |  |  | $ | 28,627 |  |  | $ | 100,492 |  |  | $ | 73,978 |
Reconciling Items: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Operating expenses |  |  | 29,363 |  |  |  | 31,139 |  |  |  | 97,689 |  |  |  | 69,166 |
Operating income (loss) |  |  | 3,402 |  |  |  | (2,512 | ) |  |  | 2,803 |  |  |  | 4,812 |
Nonoperating expense (income), net |  |  | 1,486 |  |  |  | (171 | ) |  |  | 2,915 |  |  |  | 1,192 |
Earnings (loss) before income taxes |  | $ | 1,916 |  |  | $ | (2,341 | ) |  | $ | (112 | ) |  | $ | 3,620 |
| (a) | Intersegment revenues are not significant and are eliminated to arrive at consolidated totals.
| (b) | Non-reportable operating segments and unallocated corporate expenses are reported within Corporate and Other.
The following table sets forth inventories by reportable segment. Our chief operating decision maker is not provided with any other segment asset information.
|  | December 31, |  |  | March 31, |
|  | 2022 |  |  | 2022 |
Clinical Genomics |  | $ | 14,591 |  |  | $ | 11,802 |
Sterilization and Disinfection Control |  |  | 3,022 |  |  |  | 2,176 |
Biopharmaceutical Development |  |  | 7,797 |  |  |  | 4,495 |
Calibration Solutions |  |  | 8,329 |  |  |  | 6,133 |
Total inventories |  | $ | 33,739 |  |  | $ | 24,606 |

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 34 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (e) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 26 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (d) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 15 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI https://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration